Related Experiment Video

Updated: May 17, 2026

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy
09:57

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

Published on: September 20, 2024

Evaluation of Oral Glucose Tolerance Test in Children With Epilepsy

Sotirios Varlamis1, Norma Vavatsi, Evangelos Pavlou

  • 11Department of Pediatrics, School of Medicine, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece.

Journal of Child Neurology
|October 17, 2012
PubMed

Insights

Children with refractory epilepsy show distinct glucose metabolism differences compared to those with controlled epilepsy or first-time seizures. This metabolic profile difference is evident regardless of seizure type.

Area of Science:

  • Pediatric Neurology
  • Metabolic Disorders
  • Epilepsy Research

Background:

  • Epilepsy affects children globally, with varying responses to antiepileptic drugs.
  • Understanding glucose metabolism in pediatric epilepsy is crucial for treatment strategies.
  • Drug resistance in epilepsy presents unique challenges in managing metabolic disturbances.

Purpose of the Study:

  • To investigate and compare glucose metabolism profiles in children with drug-resistant epilepsy, drug-controlled epilepsy, and first-time seizures.
  • To identify potential metabolic distinctions associated with refractory epilepsy.
  • To assess glucose tolerance and related biomarkers across different pediatric epilepsy cohorts.

Main Methods:

  • Oral glucose tolerance tests (OGTT) were administered to assess glucose metabolism.
  • Blood samples were analyzed for insulin, C-peptide, and glycosylated hemoglobin (HbA1c) levels.
  • Statistical analysis was performed to compare OGTT results and biomarker levels between study groups.

Main Results:

  • A significantly higher percentage of children with refractory epilepsy (62.07%) exhibited abnormal OGTT results compared to controlled epilepsy (25%) and first-time seizure groups (21.21%).
  • The difference in abnormal OGTT results between the refractory epilepsy group and the other two groups was statistically significant (P < .05).
  • Mean insulin, C-peptide, and HbA1c levels were within normal ranges for all participant groups.

Conclusions:

  • Refractory epilepsy in children is associated with a distinct glucose metabolism profile compared to drug-controlled epilepsy and first-time seizures.
  • These metabolic differences are observable through OGTT, irrespective of the specific seizure type.
  • The findings suggest that metabolic profiling could aid in differentiating epilepsy phenotypes.

Keywords:
HbA1cdrug-resistant epilepsyglucose metabolismglucose toleranceinsulin

More Related Videos

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test06:59

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

Published on: January 7, 2018

Related Concept Videos

Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes: